We are live on ! Find out more
KIN

Kindred Biosciences
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

72 hedge funds and large institutions have $180M invested in Kindred Biosciences in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 12

0.52% less ownership

Funds ownership: 67.94% → 67.42% (-0.52%)

4% less funds holding

Funds holding: 75 → 72 (-3)

13% less capital inflows, than outflows

Capital inflows: $13.8M | Capital outflows: $15.8M

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

Holders
72
Holders Change
-3
Holders Change %
-4%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
30
Reduced
12
Closed
10
Calls
$397​K
Puts
–
Net Calls
+$397​K
Net Calls Change
-⁠$775​K

KIN Hedge Fund Activity: Q3 2019 in Review

72 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences (KIN) for Q3 2019, worth a combined $180M — down 18% from $221M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of KIN and 6 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 30 added.

The largest buyer was Ameriprise, adding an estimated $4.55M. The largest seller was Ariel Investments, cutting an estimated $6.91M.

  • 72 institutional investors held Kindred Biosciences (KIN) as of Q3 2019, down from 75 in Q2 2019.
  • Funds reported $180M of Kindred Biosciences stock for Q3 2019, down 18% quarter-over-quarter.
  • 6 funds opened new Kindred Biosciences positions in Q3 2019 and 10 closed out, a net change of -4 holders.
  • The largest Kindred Biosciences buyer in Q3 2019 was Ameriprise, an estimated $4.55M added.
  • The largest Kindred Biosciences seller in Q3 2019 was Ariel Investments, an estimated $6.91M sold.

Based on aggregated 13F filings for Q3 2019.